-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Itorsia reported that the candidate oral therapy lucerastat failed to meet the primary endpoint, and the clinical trial for the treatment of Fabry disease was declared a failure
The expected purpose of the failed Phase III MODIFY study is to find that its oral glucosylceramide synthase inhibitor lucerastat has a positive therapeutic effect on adult patients who have been diagnosed with Fabry disease
Currently, there is hardly any well-tolerated oral treatment that can solve the above symptoms
Fabry disease is a rare genetic disease that causes damage to the nervous system.
After the trial failed, with regard to the future R&D prospects of lucerastat, Jean Peal Clozel, managing director and CEO of Itorsia, said in a statement that considering the quality of the clinical trial, the amount of data collected, and the six For some observations made during the month of double-blind placebo-controlled treatment period, Idorsia needs to continue to wait for the results of the open interim analysis before making a decision
Although the lucerastat trial failed to achieve positive results, 2021 is a very busy year for Itorsia.
Unlike Idorsia, the other two companies seem to have made breakthroughs in the regulation of Fabry disease
Reference source:
1.
2.
